ID：S07
Therapeutic Strategy：Blockade of cytokine
Synonyms：Cytokine signalling
Related Targets：phosphodiesterase (PDE)4 inhibitors; Janus kinases; adenosine 3′5′-monophosphate (cAMP); IFNγ, TNF, IL-12, IL-17 and IL-23
Related Drugs：apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab
Mechanism：Various T-cell subsets, their differentiation pathways and their signature cytokines have been identified in patients with IBD. Some of these cytokines, are important new targets for therapeutic approaches in IBD.blockade of these cytokine subunits might effectively suppress intestinal inflammation in mouse models of colitis. In particular, IL-23 inhibition was effective and prevented activation of T cells and innate lymphoid cells and tissue destruction in vivo.

Related Literature

Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells.
📅 Publication Date: 2025-07-23
📖 Source: Gastroenterology
# PMID: 9098000
BACKGROUND & AIMS: Cell-mediated immunity is a feature of Crohn's disease (CD). The heterodimer interleukin (IL)-12, produced by phagocytes, induces T-cell cytokines, primarily in…
Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody.
📅 Publication Date: 2025-07-23
📖 Source: Inflammatory bowel diseases
# PMID: 16374252
BACKGROUND: Interleukin (IL)-12p70 and IL-23 are key T helper-1 (TH1) cytokines that drive the inflammation seen in numerous models of intestinal inflammation. These molecules con…
IL-23: a master regulator in Crohn disease.
📅 Publication Date: 2025-07-23
📖 Source: Nature medicine
# PMID: 17206128
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
📅 Publication Date: 2025-07-23
📖 Source: Gastroenterology
# PMID: 18706417
BACKGROUND & AIMS: Interleukin-12 and interleukin-23 are inflammatory cytokines implicated in Crohn's disease pathophysiology. Ustekinumab is a monoclonal antibody against the p40…
A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease.
📅 Publication Date: 2025-07-23
📖 Source: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
# PMID: 24480677
BACKGROUND & AIMS: Tofacitinib, an orally administered Janus kinase inhibitor, blocks signaling through gamma-chain-containing cytokines (interleukins 2, 4, 7, 9, 15, and 21). We …
Update on Janus kinase antagonists in inflammatory bowel disease.
📅 Publication Date: 2025-07-23
📖 Source: Gastroenterology clinics of North America
# PMID: 25110261
Janus kinase (JAK) inhibitors have emerged as a novel orally administered small-molecule therapy for the treatment of ulcerative colitis and possibly Crohn disease. These molecule…